Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Zura Bio Fiscal Q4 2023 Earnings Report - CapyFin

Zura Bio

ZURA · NASDAQ🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q4 2025 -9.52%Q2 2025 +6.87%Q1 2025 -7.57%Q3 2024 -1.68%Q4 2024 +3.95%Q2 2024 -3.56%Q1 2024 -0.64%Q4 2023 +22.84%Q3 2023 +2.80%Q2 2023 -0.58%Q1 2023 -25.98%Q4 2022 -1.84%Q3 2022 Q2 2022 Q1 2022

Mar 28, 2024

•

Dec 31, 2023

Zura Bio Q4 2023 Earnings Report

Zura Bio reported full year 2023 financial results and appointed Robert Lisicki as CEO.

Key Takeaways

Zura Bio reported its full year 2023 financial results, highlighting a cash balance of $99.8 million and the appointment of Robert Lisicki as CEO. The company is focused on advancing its clinical programs, including a Phase 2 trial for tibulizumab.

Appointed Robert Lisicki as CEO, effective April 8, 2024.

Plans to initiate a Phase 2 trial of tibulizumab for systemic sclerosis in 2H 2024.

Cash and cash equivalents were $99.8 million as of December 31, 2023.

Anticipates cash and cash equivalents are sufficient to fund planned operations into 2026.

Total Revenue

EPS

-$0.3

Previous year: -$84.8